119 related articles for article (PubMed ID: 23402559)
21. Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients.
Weinreich T; Leistikow F; Hartmann HG; Vollgraf G; Dellanna F;
Hemodial Int; 2012 Jan; 16(1):11-9. PubMed ID: 22098689
[TBL] [Abstract][Full Text] [Related]
22. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
23. Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient.
Shingu Y; Nakata T; Sawai S; Tanaka H; Asai O; Tamagaki K; Nakatani K
BMC Nephrol; 2020 Jul; 21(1):275. PubMed ID: 32664894
[TBL] [Abstract][Full Text] [Related]
24. Safety of erythropoiesis stimulating agents in patients on dialysis: current issues for nephrology nurses.
Carter B; Keen M
Nephrol Nurs J; 2007; 34(3):311-5. PubMed ID: 17644875
[TBL] [Abstract][Full Text] [Related]
25. Administration of erythropoiesis-stimulating agents in patients undergoing haemodialysis: A time and motion study.
Johnson DW; Cleland B; Eris J; Rafferty T; Sud K; Chow JS
J Ren Care; 2017 Dec; 43(4):219-225. PubMed ID: 28901048
[TBL] [Abstract][Full Text] [Related]
26. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study.
de Francisco AL; Sulowicz W; Klinger M; Niemczyk S; Vargemezis V; Metivier F; Dougherty FC; Oguey D;
Int J Clin Pract; 2006 Dec; 60(12):1687-96. PubMed ID: 17109676
[TBL] [Abstract][Full Text] [Related]
27. Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa.
Pannier A; Jordan P; Dougherty FC; Bour F; Reigner B
Curr Med Res Opin; 2007 Dec; 23(12):3025-32. PubMed ID: 17961301
[TBL] [Abstract][Full Text] [Related]
28. [Current issues in erythropoietin therapy of renal anemia].
Zakar G
Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
[TBL] [Abstract][Full Text] [Related]
29. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
[TBL] [Abstract][Full Text] [Related]
30. C.E.R.A. administered once monthly corrects and maintains stable hemoglobin levels in chronic kidney disease patients not on dialysis: the observational study MICENAS II.
Martínez-Castelao A; Cases A; Coll E; Bonal J; Galceran JM; Fort J; Moreso F; Torregrosa V; Guirado L; Ruiz P;
Nefrologia; 2015; 35(1):80-6. PubMed ID: 25349927
[TBL] [Abstract][Full Text] [Related]
31. Cost analysis: treatment of chemotherapy-induced anemia with erythropoiesis-stimulating agents in five European countries.
Duran A; Spaepen E; Lamotte M; Walter E; Umuhire D; Lucioni C; Pinheiro B; Brosa M; Kutikova L; Pujol B; Van Belle S; Annemans L
J Med Econ; 2012; 15(3):409-18. PubMed ID: 22208527
[TBL] [Abstract][Full Text] [Related]
32. Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience.
Agrawal V; Mukherjee S; Kosuri R; Dumler F
Am J Ther; 2010; 17(5):469-75. PubMed ID: 19770634
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
[TBL] [Abstract][Full Text] [Related]
34. Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs.
Charytan C
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2355-62. PubMed ID: 21071515
[TBL] [Abstract][Full Text] [Related]
35. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
Nurko S; Spirko R; Law A; Dennis VW
Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
[TBL] [Abstract][Full Text] [Related]
37. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
[TBL] [Abstract][Full Text] [Related]
38. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
Berger A; Edelsberg J; Kallich J; Oster G
Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
[TBL] [Abstract][Full Text] [Related]
39. Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective.
Gauthier-Loiselle M; Michalopoulos SN; Cloutier M; Serra E; Bungay R; Szabo E; Guérin A
J Manag Care Spec Pharm; 2021 Dec; 27(12):1703-1713. PubMed ID: 34818094
[No Abstract] [Full Text] [Related]
40. Early responsiveness to continuous erythropoietin receptor activator predicts renal prognosis and is determined by a novel antioxidative marker in non-dialysis chronic kidney disease: a prospective, observational, single-center study.
Ino J; Kasama E; Kodama M; Harada T; Sato K; Eizumi H; Kawashima Y; Nitta K
Clin Exp Nephrol; 2020 Jul; 24(7):590-597. PubMed ID: 32185544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
